1. Selecting NOACs for High-Risk Patients

3. Program Goals

4. Benefit of NOACs in High-Risk Patients Meta-Analysis of Phase 3 SPAF Trial Subgroups

5. Similar Risk Factors Predicting the Risk of Thromboembolism and Bleeding in Patients With AF

6. Antithrombotic Treatment Based on Stroke Risk Findings From GLORIA-AF Registry

7. Recommendations for Stroke Prevention in Patients With AF

8. Global Differences in Antithrombotic Treatment Findings From GLORIA-AF Registry

9. Evolution of Baseline Antithrombotic Treatment: Sequential Cohorts of GARFIELD-AF Registry

10. Increasing Use of VKA With Increasing Risk for Stroke Insights From the GARFIELD-AF Registry

11. Patient Case Managing Patients With a Prior Event

12. Initiation of OAC Therapy After Stroke

13. Patients With AF and Prior Stroke or TIA NOAC vs VKA Meta-Analysis

14. Cancer in Patients at Risk for Thrombosis

15. Cancer in Patients With AF

16. Hokusai VTE-Cancer Clinical Outcomes in Patients With Cancer at Risk for VTE

17. Patient Case High Risk of Bleeding

18. Patients With AF and High Risk of Bleeding

19. NOAC Meta-Analysis in Secondary Stroke Prevention

20. Valvular Atrial Fibrillation and Bioprosthetic Heart Valves

21. Mechanical Heart Valves Dabigatran vs VKA in the RE-ALIGN Study

22. NOACs in Patients With AF and Valvular Heart Disease Meta-Analysis of SPAF NOAC Trials

23. Edoxaban vs VKA in Patients With AF and Valvular Heart Disease

24. Guideline Recommendations for Managing AF in Patients With Valvular Heart Disease

25. Bleeding in Patients With AF on Oral Anticoagulant and Antiplatelets Meta-Analysis of SPAF NOAC Trials

26. RE-DUAL PCI Primary Endpoint: Time to First Bleeding Event

27. Antithrombotic Therapy After ACS and PCI

28. Renal and Hepatic Impairment

29. Renal Function Meta-Analysis of All NOACs vs Warfarin

30. Renal Considerations for NOACs Clearance and Dosing

31. Hepatic Considerations for NOACs Clearance and Metabolism

32. Meta-Analysis of Risk for Drug-Induced Liver Injury With NOACs

33. Edoxaban vs Warfarin in Patients With AF and Hepatic Disease

34. Extremes in Weight

35. Relationship Between BMI and Outcomes Insights From the ENGAGE AF-TIMI 48 Trial

36. Use of NOACs in Extremes of Weight

37. Factors to Consider in Selecting the Appropriate NOAC

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)